Sept. 3, 2014
-- Revenue Forward View
As Sambria Pharmaceuticals continues to increase its rapidly growing sales force, distribution partnerships, international strategic alliances and web marketing presence, its outlook for future revenue growth continues to expand at a nearly geometric rate. Uses for the Sambria Pharmaceuticals topical pain management medication line also continue to grow as more and more healthcare practitioners and retail outlets both use and offer its products to patients and consumers. The increase in the combination of potential distribution channels as well as uses offered to the public by these channels positions Sambria Pharmaceuticals to nearly shatter its previous revenue records. Sambria Pharmaceuticals managers have been planning the roll out of additional consumer healthcare products beginning mid-year of 2015.
Chief Executive Officer, Michael Greenspan, states “Future development of topical pain and discomfort relieving medications will dramatically increase Sambria Pharmaceuticals offerings to an increasing number of healthcare specialties well into the second half of this decade. We anticipate that our investors and trade partners will be very satisfied with the financial rewards provided by the upcoming array of near-term new product offerings into the marketplace.”
Near-term Future Development
Sambria Pharmaceuticals managers are being fairly tight-lipped when it comes to public announcements of future development plans. Chief Operations Officer, Joseph Valenti, announced, “I am willing to publicly announce that we have several new development projects currently on the table and in-process. A prescription version of our NeuroMed7 Topical Anesthetic Cream has been requested by one of our top prospective aesthetic device distribution trade partners, and we are seriously considering this option presently. Our primary consideration in creating the prescription version is public safety as well as regulatory concerns.
We also currently have oral applications in process as well. At such time when we are closer to marketing these applications, Sambria Pharmaceuticals will announce publicly its updated plans and new offerings.”
Sambria Pharmaceuticals has filed a volume of patent applications for its novel topical drug delivery systems. Plans for a handful of Sambria Pharmaceuticals near-term future development projects will be determined by mid-year 2015, as well.
For information about Sambria Pharmaceuticals and its current OTC medications lines, visit www.sambriapharma.com.
There is a high potential for topical trans-dermal delivery of aesthetic applications using a combination of the Sambria Pharmaceuticals delivery system combined with specific nano-technologies that could have a strong positive impact in the aesthetic medicine specialties.